Phase I study of Convection-enhanced delivery of Nimustine Hydrochloride combined with oral Temozolomide against recurrent gliomas at brainstem - CED of ACNU plus oral TMZ against recurrent gliomas at brainstem: Phase I study

Department of Neurosurgery, Tohoku University Graduate School of Medicine0 个研究点目标入组 15 人开始时间: 2011年2月22日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Co-existence of uncured cancer. 2) Co-existence of meningitis or pneumonia that require treatment. 3) Pregnant women or possibly pregnant women or breast feeding women 4) Existence of active inflammation (CRP>2.0) 5) Severe liver dysfunction (GOT>100 IU/l or GPT>100 IU/l) 6) Existence of bone marrow insufficiency: WBC(<3,000/mm3), Hb (<8.0 g/dl), Plt(<10x104/mm3) 7) Renal dysfunction: Cre (>1.5 mg/dl) 8) Existence of hemorrhagic diathesis 9) Patients taking anti-coagulants or anti-platelet agents. 10) Existence of mental disorder that makes participation to this study difficult. 11) Poor control of diabetes mellitus 12) Past history of acute myocardial infarction within 3 months or unstable angina. 13) Past history of pulmonary fibrosis or interstitial pneumoniae.

发起方

Department of Neurosurgery, Tohoku University Graduate School of Medicine